The company has reported net sales of $5.47 million, for the second quarter of 2009, compared to $6.25 million for same period of 2008.
Transgenomic has reported a net loss of $1.68 million or $0.03 per share, for the first half of 2009, compared to a net income of $223,000 or $0.00 per share, for the same period of 2008.
The company has reported net sales of $10.46 million, for the first half of 2009, compared to $12.5 million for the same period of 2008.
Craig Tuttle, president and CEO of Transgenomic, said: "It is rewarding to see a sales rebound well above our first quarter results. While we have not quite reached quarterly sales at our former run rate prior to the economy decline, sales in second quarter did increase $500,000 above first quarter.
"In addition, we do see interest in new instrument sales opportunities throughout the remainder of this fiscal year and next year. Budget approval processing will drive the timing of these sales. We are seeing several new projects in our Pharmacogenomics lab which have the potential to move forward toward full clinical trial studies as well as a number of discovery projects with a similar outcome potential."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index